ClinicalTrials.Veeva

Menu

Safety and Efficacy of Remote Ischemic Conditioning for Acute Ischemic Stroke

Y

Yi Yang

Status

Enrolling

Conditions

Acute Ischemic Stroke

Treatments

Procedure: Sham remote ischemic conditioning
Procedure: Remote ischemic conditioning

Study type

Interventional

Funder types

Other

Identifiers

Details and patient eligibility

About

The purpose of this study is to determine the efficacy and safety of remote ischemic conditioning for acute ischemic stroke.

Full description

In this study, 2210 cases of ischemic stroke in 72 hours were included in 10 centers in China according to the principle of random, and parallel control. The experimental group receive basic treatment and remote ischemic conditioning for 200mmHg, 2 times per day for 7 consecutive days. The control group receive basic treatment and remote ischemic conditioning control for 60mmHg, 2 times per day for 7 consecutive days. Two groups will be followed up for 90 days to evaluate the efficacy and safety of remote ischemic conditioning in treating acute ischemic stroke.

Enrollment

2,210 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

    1. Age≥18 years, regardless of sex.
    1. Patients with clinically definite diagnosis of acute ischemic stroke and able to commence RIC treatment within 72 hours of stroke onset.
    1. Baseline NIHSS ≥ 4, ≤ 24.
    1. Baseline mRS ≤ 2;
    1. Signed and dated informed consent is obtained.

Exclusion criteria

    1. Patients who undergo thrombolytic therapy or endovascular treatment.
    1. The patients who had the contraindication of remote ischemic conditioning treatment, such as severe soft tissue injury, fracture, or vascular injury in the upper limb. Acute or subacute venous thrombosis, arterial occlusive disease, subclavian steal syndrome, etc.
    1. Other intracranial lesions, such as cerebrovascular malformation cerebral venous diseases, tumors,s and other diseases involving the brain.
    1. Pregnant or lactating women.
    1. Previous remote ischemic conditioning therapy or similar treatment.
    1. Severe hepatic and renal dysfunction.
    1. Patients with a life expectancy of less than 3 months or patients unable to complete the study for other reasons.
    1. Unwilling to be followed up or treated for poor compliance.
    1. He/She is participating in other clinical research or has participated in other clinical research or has participated in this study within 3 months prior to admission.
    1. Other conditions that the researchers think are not suitable for the group.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

2,210 participants in 2 patient groups, including a placebo group

RIC+Standard medical treatment
Active Comparator group
Description:
Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 200 mm Hg. RIC will be conducted twice daily for 7 consecutive days. Additionally, the patients will be treated with standard medical treatment according to the Guidelines for diagnosis and treatment of acute ischemic stroke in China 2014.
Treatment:
Procedure: Remote ischemic conditioning
Sham RIC+Standard medical treatment
Placebo Comparator group
Description:
Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 60 mm Hg. RIC will be conducted twice daily for 7 consecutive days. Additionally, the patients will be treated with standard medical treatment according to the Guidelines for diagnosis and treatment of acute ischemic stroke in China 2014.
Treatment:
Procedure: Sham remote ischemic conditioning

Trial contacts and locations

1

Loading...

Central trial contact

Yi Yang, MD, PhD; Zhenni Guo, MD, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems